49,363 Shares of Danaher Corporation $DHR Bought by HF Advisory Group LLC

HF Advisory Group LLC purchased a new position in Danaher Corporation (NYSE:DHR) during the third quarter, Holdings Channel reports. The fund purchased 49,363 shares of the conglomerate’s stock, valued at approximately $10,936,000. Danaher accounts for 2.6% of HF Advisory Group LLC’s holdings, making the stock its 3rd largest holding.

Several other hedge funds and other institutional investors have also recently bought and sold shares of DHR. EP Wealth Advisors LLC purchased a new stake in shares of Danaher during the second quarter worth about $3,807,000. Puzo Michael J purchased a new position in Danaher during the 2nd quarter valued at about $8,624,000. First Nebraska Trust Co bought a new position in Danaher during the 2nd quarter valued at approximately $14,106,000. Madison Asset Management LLC bought a new stake in shares of Danaher in the 2nd quarter worth approximately $85,451,000. Finally, Colton Groome Financial Advisors LLC purchased a new stake in shares of Danaher in the 3rd quarter worth about $592,000. Institutional investors own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on DHR shares. Evercore restated an “outperform” rating and issued a $230.00 price objective on shares of Danaher in a report on Monday, July 6th. TD Cowen lowered their price objective on Danaher from $240.00 to $236.00 and set a “buy” rating for the company in a research note on Wednesday, July 22nd. Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a report on Saturday. Royal Bank Of Canada raised their price target on Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a report on Monday. Finally, Wells Fargo & Company cut their price objective on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $235.23.

Danaher Stock Up 1.2%

Danaher stock opened at $220.15 on Friday. Danaher Corporation has a 12 month low of $160.93 and a 12 month high of $242.80. The stock has a fifty day simple moving average of $211.38 and a two-hundred day simple moving average of $194.62. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The firm has a market cap of $154.76 billion, a price-to-earnings ratio of 39.10, a PEG ratio of 2.71 and a beta of 0.76.

Danaher (NYSE:DHR) last released its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The company had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. During the same period last year, the firm posted $0.77 earnings per share. Danaher’s revenue was up 5.5% compared to the same quarter last year. Equities analysts predict that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.40 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. Danaher’s payout ratio is currently 28.42%.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.